Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correlation of Plasma Lyso-GL1 Levels with Clinical Phenotype and Treatment Decisions in Patients with Gaucher Disease.

Molecular genetics and metabolism·2025

Same author

The effect of dietary tryptophan supplementation, and an oral tryptophan challenge, on urinary excretion of 5-hydroxyindoleacetic acid in domestic dogs.

Frontiers in veterinary science·2025

Same author

Case Report: Trilostane therapy in a dog with recurrent adrenocortical carcinoma producing an array of steroid hormones.

Frontiers in veterinary science·2025

Same author

Combination of Hydroxypropyl-Beta-Cyclodextrin and Trehalose for Improved Stability of Spray-Dried Monoclonal Antibodies.

Molecular pharmaceutics·2025

Same author

Exploring How Antibody Format Drives Clearance from the Brain.

Molecular pharmaceutics·2024

Same author

Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40.

Bioconjugate chemistry·2024

Same journal

Green, renewable, or low-carbon? A framework for informed solvent selection in pharmaceutical sciences.

Journal of pharmaceutical sciences·2026

Same journal

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI.

Journal of pharmaceutical sciences·2026

Same journal

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026

Same journal

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026

Same journal

A mathematical framework for predicting tablet weight variability from blend particle size distribution and tooling geometry.

Journal of pharmaceutical sciences·2026

Same journal

Recrystallization can stop nitrosamine formation in ranitidine hydrochloride.

Journal of pharmaceutical sciences·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 12, 2025

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Stability Comparison Between Microglassification and Lyophilization Using a Monoclonal Antibody.

Karthik Balakrishna Chandrababu¹, Aadithya Kannan², John R Savage¹

¹Lindy Biosciences, 627 Davis Dr. #400 Morrisville, North Carolina 27560, United States.

Journal of Pharmaceutical Sciences

|October 20, 2023

Summary

This summary is machine-generated.

Microglassification™ offers a novel method for creating stable solid-state biologics, like monoclonal antibodies, by avoiding heat stress during dehydration. This new technique demonstrates comparable protein stability to traditional lyophilization.

Keywords:

Antibody drug Chemical stability Dehydration, Lyophilization Microparticle(s)Monoclonal antibody(s)Protein formulation Protein(s)Solid-state stability

More Related Videos

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Controlling Particle Fraction in Microporous Annealed Particle Scaffolds for 3D Cell Culture

Controlling Particle Fraction in Microporous Annealed Particle Scaffolds for 3D Cell Culture

Published on: October 28, 2022

Related Experiment Videos

Last Updated: Jul 12, 2025

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Controlling Particle Fraction in Microporous Annealed Particle Scaffolds for 3D Cell Culture

Controlling Particle Fraction in Microporous Annealed Particle Scaffolds for 3D Cell Culture

Published on: October 28, 2022

Area of Science:

Biopharmaceutical formulation
Protein stabilization technologies
Solid-state drug delivery

Background:

Lyophilization and spray drying are common but challenging for biologics.
Challenges include protein thermal stability, cost, and manufacturing scalability.
Novel dehydration methods are needed for improved solid-state biologic formulations.

Purpose of the Study:

To evaluate Microglassification™ as a novel dehydration technology for biologics.
To compare the molecular stability of monoclonal antibody formulations produced by Microglassification™ versus lyophilization.
To assess the viability of Microglassification™ for producing stable solid-state monoclonal antibody formulations.

Main Methods:

Microglassification™ uses solvent extraction for rapid dehydration at ambient temperatures.
Lyophilization and Microglassification™ were used to process a monoclonal antibody formulation.
Formulations were subjected to stability testing at 40 °C for 3 months and 25 °C for 6 months.

Main Results:

Both lyophilization and Microglassification™ yielded chemically stable monoclonal antibody formulations.
No significant differences were observed in percent monomer, charge variants, or antigen binding between the two methods.
Microglassification™ produced spherical, dense, and chemically stable microparticles.

Conclusions:

Microglassification™ is a viable alternative to lyophilization for producing stable solid-state monoclonal antibody formulations.
The ambient temperature processing of Microglassification™ mitigates thermal stress on biologics.
This technology shows promise for improving the manufacturing of solid-state biologics.